Amgen Says Dazodalibep Meets Primary Endpoint In Phase 3 Sjögren's Disease Trial
A
AMGN• Phase 3 trial results
Sept. 22 (Reuters) - Amgen Inc AMGN.O:
•
Amgen Says Dazodalibep Meets Primary Endpoint In Phase 3 Sjögren's Disease Trial - AMGN News | Rallies
